NCT04106076View on ClinicalTrials.gov

Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 11, 2019

Primary Completion Date

December 5, 2019

Study Completion Date

December 5, 2019

Conditions
Acute Myeloid Leukaemia
Interventions
BIOLOGICAL

UCART123

Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor

Sponsors

Lead Sponsor

Cellectis S.A.
All Listed Sponsors
lead

Cellectis S.A.

INDUSTRY

NCT04106076 - Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter